Suven Life Sciences granted patents for neurodegenrative drug

Pharmaceutical firm Suven Life Sciences today said it has been granted product patents by Eurasia, Japan and Mexico for drug used in the treatment of neurodegenrative diseases.
Neurodegenrative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
In a BSE filing the company said that it has been granted "one product patent from Eurasia, one product patent from Japan and one product patent from Mexico corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases".
These patents are valid until 2029, the company said.
Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 13 granted patents 12 from Eurasia, 12 from Japan and 17 from Mexico.
"These patents are exclusive intellectual property of Suven...Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2," Suven Life Sciences said.